ArticleBMC microbiology2026
Highly sensitive and rapid determination of Coxsackievirus A16 using restriction endonuclease-mediated reverse transcription multiple cross displacement amplification.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAs a major etiological agent of hand, foot, and mouth disease in humans, Coxsackievirus A16 (CVA16) exerts a detrimental impact on the health of infants and toddlers. In the absence of effective antiviral drugs and vaccines targeting CVA16, a diagnostic strategy with sensitivity, specificity and rapid response is indispensable for the prevention and management of CVA16 infection.
resultsIn this study, a novel molecular diagnostic approach, coupling real-time fluorescence technique with reverse transcription multiple cross-displacement amplification (RT-MCDA), was developed for the sensitive, rapid, and specific identification of CVA16 (termed CVA16-E-RT-MCDA). To construct the system, a unique set of CVA16-E-RT-MCDA primers was successfully designed targeting the VP1 gene of CVA16, and the optimal conditions for CVA16-E-RT-MCDA were determined to be 63 ℃ for 35 min. The limit of detection for the CVA16-E-RT-MCDA assay was 14 copies/µL (approximately 70 copies per reaction) for the RNA standard template of CVA16. The CVA16-E-RT-MCDA assay exhibited high specificity and anti-interference. The findings demonstrated that the applicability of the CVA16-E-RT-MCDA method was promptly and successfully confirmed using clinical samples from patients with suspected CVA16 infections.
conclusionsThe CVA16-E-RT-MCDA assay established in the present study exhibits sensitivity, specificity and rapidity for CVA16 detection, rendering it a promising diagnostic tool for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.